VCYT vs. PFE

Last updated Apr 1, 2026

Compare and contrast key facts about Veracyte, Inc. (VCYT) and Pfizer Inc. (PFE).

Performance

VCYT vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Veracyte, Inc. (VCYT) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

VCYT vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VCYT Veracyte, Inc.	-23.49%	6.31%	43.95%	15.93%	-42.40%	-15.82%	75.29%	121.94%	92.65%	-15.63%
PFE Pfizer Inc.	14.66%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	-6.91%	24.82%	15.90%

Fundamentals

Market Cap VCYT : $2.62B PFE : $159.66B
EPS VCYT : $0.83 PFE : $1.36
PE Ratio VCYT : 38.99 PFE : 20.61
PEG Ratio VCYT : 0.24 PFE : 0.37
PS Ratio VCYT : 5.00 PFE : 2.56
PB Ratio VCYT : 2.00 PFE : 1.72
Total Revenue (TTM) VCYT : $517.15M PFE : $62.58B
Gross Profit (TTM) VCYT : $362.53M PFE : $44.01B
EBITDA (TTM) VCYT : $74.62M PFE : $15.10B

Returns By Period

In the year-to-date period, VCYT achieves a -23.49% return, which is significantly lower than PFE's 14.66% return. Over the past 10 years, VCYT has outperformed PFE with an annualized return of 19.69%, while PFE has yielded a comparatively lower 4.32% annualized return.

VCYT

• 1D: 5.81%
• 1M: -11.97%
• YTD: -23.49%
• 6M: -6.18%
• 1Y: 8.63%
• 3Y*: 13.04%
• 5Y*: -9.38%
• 10Y*: 19.69%

PFE

• 1D: 1.12%
• 1M: 1.56%
• YTD: 14.66%
• 6M: 14.02%
• 1Y: 18.86%
• 3Y*: -6.22%
• 5Y*: -0.14%
• 10Y*: 4.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VCYT vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VCYT

VCYT Risk / Return Rank: 46
VCYT Sharpe Ratio Rank: 47
VCYT Sortino Ratio Rank: 48
VCYT Omega Ratio Rank: 45
VCYT Calmar Ratio Rank: 46
VCYT Martin Ratio Rank: 46

PFE

PFE Risk / Return Rank: 65
PFE Sharpe Ratio Rank: 67
PFE Sortino Ratio Rank: 61
PFE Omega Ratio Rank: 59
PFE Calmar Ratio Rank: 69
PFE Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VCYT vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Veracyte, Inc. (VCYT) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VCYT	PFE	Difference
Sharpe ratio Return per unit of total volatility	0.16	0.71	-0.55
Sortino ratio Return per unit of downside risk	0.72	1.17	-0.45
Omega ratio Gain probability vs. loss probability	1.08	1.15	-0.06
Calmar ratio Return relative to maximum drawdown	0.18	1.32	-1.14
Martin ratio Return relative to average drawdown	0.41	3.18	-2.77
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VCYT vs. PFE - Sharpe Ratio Comparison

The current VCYT Sharpe Ratio is 0.16, which is lower than the PFE Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of VCYT and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VCYT	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.16	0.71	-0.55
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.15	-0.01	-0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.32	0.18	+0.14
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.26	-0.14

Correlation

The correlation between VCYT and PFE is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VCYT vs. PFE - Dividend Comparison

VCYT has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.13%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
VCYT Veracyte, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer Inc.	6.13%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Drawdowns

VCYT vs. PFE - Drawdown Comparison

The maximum VCYT drawdown since its inception was -81.19%, which is greater than PFE's maximum drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for VCYT and PFE.

Drawdown Indicators

	VCYT	PFE	Difference
Max Drawdown Largest peak-to-trough decline	-81.19%	-58.96%	-22.23%
Max Drawdown (1Y) Largest decline over 1 year	-39.23%	-12.59%	-26.64%
Max Drawdown (5Y) Largest decline over 5 years	-72.96%	-58.96%	-14.00%
Max Drawdown (10Y) Largest decline over 10 years	-81.19%	-58.96%	-22.23%
Current Drawdown Current decline from peak	-60.42%	-42.75%	-17.67%
Average Drawdown Average peak-to-trough decline	-48.28%	-17.33%	-30.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.00%	6.13%	+10.87%

Volatility

VCYT vs. PFE - Volatility Comparison

Veracyte, Inc. (VCYT) has a higher volatility of 16.05% compared to Pfizer Inc. (PFE) at 6.75%. This indicates that VCYT's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VCYT	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.05%	6.75%	+9.30%
Volatility (6M) Calculated over the trailing 6-month period	40.87%	18.50%	+22.37%
Volatility (1Y) Calculated over the trailing 1-year period	55.36%	26.73%	+28.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.23%	25.46%	+38.77%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.38%	23.90%	+37.48%

Financials

VCYT vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Veracyte, Inc. and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

VCYT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported a gross profit of 101.97M and revenue of 140.64M. Therefore, the gross margin over that period was 72.5%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a gross profit of 12.29B and revenue of 17.56B. Therefore, the gross margin over that period was 70.0%.

VCYT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported an operating income of 37.20M and revenue of 140.64M, resulting in an operating margin of 26.5%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported an operating income of 3.69B and revenue of 17.56B, resulting in an operating margin of 21.0%.

VCYT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Veracyte, Inc. reported a net income of 41.15M and revenue of 140.64M, resulting in a net margin of 29.3%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a net income of -1.65B and revenue of 17.56B, resulting in a net margin of -9.4%.